Navigation Links
Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Date:6/18/2013

> has the rights to develop and commercialise safinamide in Japan and other key Asian territories. Newron's additional projects are primarily addressed towards highly promising treatments for rare diseases and are at various stages of preclinical and clinical development, including sNN0031 for Parkinson's disease, sarizotan for Rett's syndrome, sNN0029 for ALS, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia. http://www.newron.com

About Zambon

Zambon is a leading Italian pharmaceutical and fine-chemical multinational company, that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care, and is very strongly committed to its entry into the CNS space. Zambon SpA produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. The Group is strongly working on the treatment of the chronic respiratory diseases as BPCO and on the CNS therapeutic area with safinamide for the Parkinson treatment. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 15 countries with more than 2,600 employees with manufacturing units in Italy, Switzerland, France, China and Brazil.  For details on Zambon please see: http://www.zambongroup.com

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current
'/>"/>

SOURCE Newron Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
9. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes JINS MEME,s ... Co., Ltd. will launch JINS MEME "ACADEMIC PACK" in late ... $5,000 (without tax /including two pairs of JINS MEME and ... solution of "JINS MEME" to academic researchers, and it enables ... electrooculography and six-axis sensors without API. (*Physiological data that can ...
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 26, 2014 /PRNewswire/ ... AEX: PHIA) today announced expanded availability of ... including DuraDiagnost, DigitalDiagnost, MobileDiagnost wDR, MobileDiagnost Opta[i] , ... of these solutions now available in the U.S., ... global markets, the portfolio offers Philips, customers innovative ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Exceptionally high costs.  Long research and development cycles.  Low ...  Dependence on out-dated information technology options.  It,s not just ... information being wasted.   Such ... have led to the formation of a new company, ...
... -- XIANYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... ... var ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Medicine Technology:RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 2RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 3RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 4Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 2Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 3Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 4Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 5Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 6Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 7Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 8Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 9Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 10Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 11Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 12Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 13Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 14Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 15
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... This is a professional and in ... an overview analysis, the report introduces Insulin basic ... industry overview, policy analysis, and news analysis, etc. ... information on policy, plans for Insulin Market product ... more. , This report also provides ...
(Date:11/27/2014)... 2014 At The Little Gym, we ... came as no surprise when a recent study confirmed ... success. The Journal of Pediatrics found that ... tasks during the school years may be important not ... The study monitored two groups of children; those that ...
(Date:11/27/2014)... 2014 The Emerald Cup 2014 Competition ... At This Year’s Entries | SKUNK Magazine – Proudly ... Two At Their Resort, Pure Garden, In Negril, Jamaica ... Hempcon, The Emerald Cup is presented by locals, for ... of California’s original cannabis industry." – SFGate, Smell The ...
(Date:11/27/2014)... November 27, 2014 In addition to ... an important gift home this holiday season and become ... disease. Visiting with relatives over the holidays may raise ... members. Although some change in cognitive ability can occur ... of normal aging. Recognizing the difference between normal aging ...
Breaking Medicine News(10 mins):Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 2Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 2Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 3Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 5
... Athens, Ga. - Pharmaceutical companies and universities are racing to ... RNA interference to treat a host of diseases. Now, a ... powerful tool: Researchers at the University of Georgia have demonstrated ... as a tool in the development of vaccines. , ...
... Dec. 10 /PRNewswire/ - Over 830 staff members are ... District,s newest fitness challenge. The 322 mile virtual race ... online challenge and it,s proving successful with less work ... Lee County School District has delivered fitness ...
... A University of British Columbia geneticist has discovered a gene ... uveal melanoma. , Catherine Van Raamsdonk, an assistant professor of ... team of researchers, have discovered a genetic mutation in a ... cent of the cases of uveal melanoma. , The findings, ...
... survey cites misperceptions regarding need for vaccination and a lack of ... , ... Bethesda, MD (PRWEB) December 10, 2008 -- A ... one-third (29.6 percent) have been vaccinated against the flu this season. ...
... superior to vitamin supplementation for cancer prevention. , ... ... of announcements two weeks ago that vitamin supplements A thru E ... more medical announcements with the same conclusions regarding prostate cancer. While ...
... 10 Markel Corporation is,pleased to announce the launch ... product. DataBreach(SM) helps businesses manage,risk associated with their reliance ... in their custody or care. , ... the increase in identity theft,that has been plaguing businesses ...
Cached Medicine News:Health News:Study first to show that RNA interference can facilitate vaccine development 2Health News:Study first to show that RNA interference can facilitate vaccine development 3Health News:Lee County School District online wellness program inspires employees to walk 200 million steps in 2 months 2Health News:UBC researchers discover gene mutation that causes eye cancer 2Health News:Mid-Season Flu Immunization Rates are Too Low 2Health News:Mid-Season Flu Immunization Rates are Too Low 3Health News:Mid-Season Flu Immunization Rates are Too Low 4Health News:Mid-Season Flu Immunization Rates are Too Low 5Health News:Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements 2Health News:Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage 2
... For treatment of carpal tunnel syndrome, mild ... following cast removal. The perforated suede ... the wrist, wicking away moisture for long ... metal splint prevents painful wrist flexion, and ...
... orthotic elbow system that can be used in ... proximal ulnar fractures or post reconstructive surgery where ... highly flexible system that provides you with a ... that best fits your patients needs. Two ...
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Worn by many professional athletes, EpiTrain is our most popular elbow support....
Medicine Products: